Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. (отвара нови прозор)

Barillari G, Pasca S, Barillari A, De Angelis V.

Извор‎: Blood Transfus 2012;10(1):87-94.

Индекс‎: PubMed 22044952

DOI‎: 10.2450/2011.0030-11

https://www.ncbi.nlm.nih.gov/pubmed/22044952 (отвара нови прозор)

Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (отвара нови прозор)

Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R; American College of Chest Physicians.

Извор‎: Chest 2012;141(2 Suppl):e326S-50S.

Индекс‎: PubMed 22315266

DOI‎: 10.1378/chest.11-2298

https://www.ncbi.nlm.nih.gov/pubmed/22315266 (отвара нови прозор)

Pharmacological prophylaxis of bleeding in surgical patients treated with aspirin. (отвара нови прозор)

Flordal PA.

Извор‎: Eur J Anaesthesiol Suppl 1997;14:38-41.

Индекс‎: PubMed 9088834

https://www.ncbi.nlm.nih.gov/pubmed/9088834 (отвара нови прозор)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (отвара нови прозор)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Извор‎: Lancet 2015;385(9982):2077-87.

Индекс‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (отвара нови прозор)

How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. (отвара нови прозор)

Goodnough LT, Shander A.

Извор‎: Blood 2011;117(23):6091-9.

Индекс‎: PubMed 21411756

DOI‎: 10.1182/blood-2010-11-316075

https://www.ncbi.nlm.nih.gov/pubmed/21411756 (отвара нови прозор)

Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. (отвара нови прозор)

Hanke AA, Joch C, Görlinger K.

Извор‎: Br J Anaesth 2013;110(5):764-72.

Индекс‎: PubMed 23335567

DOI‎: 10.1093/bja/aes501

https://www.ncbi.nlm.nih.gov/pubmed/23335567 (отвара нови прозор)

Reversing the effects of antiplatelet agents in the setting of intracranial hemorrhage: a look at the literature. (отвара нови прозор)

Jaben EA, Mulay SB, Stubbs JR.

Извор‎: J Intensive Care Med 2015;30(1):3-7.

Индекс‎: PubMed 25492811

DOI‎: 10.1177/0885066613487298

https://www.ncbi.nlm.nih.gov/pubmed/25492811 (отвара нови прозор)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (отвара нови прозор)

Levi M, Eerenberg E, Kamphuisen PW.

Извор‎: J Thromb Haemost 2011;9(9):1705-12.

Индекс‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (отвара нови прозор)

Emergency reversal of warfarin anticoagulation. (отвара нови прозор)

Lin Y, Callum J.

Извор‎: CMAJ 2010;182(18):2004.

Индекс‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (отвара нови прозор)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (отвара нови прозор)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Извор‎: Thromb Haemost 2012;108(2):217-24.

Индекс‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (отвара нови прозор)

Recent advances in the development of specific antidotes for target-specific oral anticoagulants. (отвара нови прозор)

Mo Y, Yam FK.

Извор‎: Pharmacotherapy 2015;35(2):198-207.

Индекс‎: PubMed 25644580

DOI‎: 10.1002/phar.1532

https://www.ncbi.nlm.nih.gov/pubmed/25644580 (отвара нови прозор)

Idarucizumab for dabigatran reversal - full cohort analysis. (отвара нови прозор)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Извор‎: N Engl J Med 2017;377(5):431-41.

Индекс‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (отвара нови прозор)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (отвара нови прозор)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Извор‎: Anesth Analg 2011;113(4):703-10.

Индекс‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (отвара нови прозор)

Oral anticoagulation in surgical procedures: risks and recommendations. (отвара нови прозор)

Torn M, Rosendaal FR.

Извор‎: Br J Haematol 2003;123(4):676-82.

Индекс‎: PubMed 14616972

https://www.ncbi.nlm.nih.gov/pubmed/14616972 (отвара нови прозор)

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. (отвара нови прозор)

Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW.

Извор‎: Blood 2012;119(9):2172-4.

Индекс‎: PubMed 22383791

DOI‎: 10.1182/blood-2011-11-393587

https://www.ncbi.nlm.nih.gov/pubmed/22383791 (отвара нови прозор)